BTCC / BTCC Square / Global Cryptocurrency /
Wells Fargo Analyst Upgrades Merck (MRK) to Buy, Stock Rises 4%

Wells Fargo Analyst Upgrades Merck (MRK) to Buy, Stock Rises 4%

Published:
2025-11-24 19:11:02
15
2
BTCCSquare news:

Merck & Co. (MRK) shares climbed 4% on Monday after Wells Fargo's top analyst Mohit Bansal upgraded the pharmaceutical giant from Hold to Buy. The bullish call came with a significant price target increase—from $90 to $125—reflecting confidence in Merck's pipeline and its ability to offset revenue risks posed by the 2028 patent expiration of its flagship cancer drug, Keytruda.

Bansal highlighted a "catalyst-rich period" over the next 12-18 months, with multiple pipeline readouts expected. The analyst no longer anticipates a steep revenue decline in the 2029-2031 window, citing Merck's strategic business developments and new drug launches. At 8.7x 2026 estimated earnings, he argues the stock is undervalued given its portfolio strength.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.